Postural Dizziness and Orthostatic Hypotension with Aripiprazole
Postural dizziness and orthostatic hypotension are uncommon with aripiprazole, occurring in approximately 0.5-1% of patients, which is substantially lower than placebo rates and far less frequent than with other antipsychotics.
Incidence Data from FDA Drug Label
According to FDA-approved labeling, the incidence of orthostatic hypotension-associated events in short-term placebo-controlled trials was 1:
Adults (n=2,467):
- Orthostatic hypotension: 1% (vs. 0.3% placebo)
- Postural dizziness: 0.5% (vs. 0.3% placebo)
- Syncope: 0.5% (vs. 0.4% placebo)
Pediatric patients ages 6-18 (n=732):
- Orthostatic hypotension: 0.5% (vs. 0% placebo)
- Postural dizziness: 0.4% (vs. 0% placebo)
- Syncope: 0.2% (vs. 0% placebo)
Objective Orthostatic Changes
Clinically significant orthostatic blood pressure changes (≥20 mmHg systolic drop with ≥25 bpm heart rate increase) occurred in only 4% of adults and 0.4% of pediatric patients on aripiprazole, compared to 2% and 1% on placebo respectively 1. This minimal difference from placebo indicates aripiprazole has negligible orthostatic effects.
Mechanism and Clinical Context
Aripiprazole may cause orthostatic hypotension through α1-adrenergic receptor antagonism 1. However, its partial agonist properties at dopamine and serotonin receptors appear to mitigate this effect compared to full antagonists like other antipsychotics.
The FDA label notes that aripiprazole can cause falls due to somnolence, postural hypotension, and motor instability, but emphasizes this risk is primarily relevant for patients with 1:
- Pre-existing cardiovascular disease (MI, ischemic heart disease, heart failure, conduction abnormalities)
- Cerebrovascular disease
- Dehydration or hypovolemia
- Concurrent antihypertensive medications
Comparative Context
The guideline evidence discusses clozapine's postural hypotension rates of 9-40% 2, highlighting that aripiprazole's <1% incidence represents a dramatically safer cardiovascular profile. Interestingly, aripiprazole is actually mentioned as a potential treatment for clozapine-induced side effects (sedation and nocturnal enuresis) 2, suggesting its favorable tolerability profile.
Clinical Recommendations
For most patients, routine orthostatic vital sign monitoring is unnecessary when initiating aripiprazole. However, measure lying and standing blood pressure in patients with:
- Age ≥65 years
- Known cardiovascular or cerebrovascular disease
- Concurrent antihypertensive therapy
- History of syncope or falls
- Dehydration risk factors
If orthostatic symptoms develop:
- Counsel patients to rise slowly from sitting/lying positions
- Ensure adequate hydration (particularly in hot climates)
- Consider compression stockings
- Reassess need for concurrent medications that lower blood pressure
The evidence does not support dose reduction or discontinuation of aripiprazole for mild orthostatic symptoms, as the incidence is minimal and typically manageable with conservative measures 1.